HealthcareServices

Predictive And Presymptomatic Testing Market Report 2026: Strategic Insights and Revenue Outlook

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the predictive and presymptomatic testing market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Predictive And Presymptomatic Testing Market show for the 2026–2030 period?

The predictive and presymptomatic testing market has experienced significant growth in recent years. Its valuation is anticipated to increase from $5.78 billion in 2025 to $6.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The expansion observed in prior periods can be attributed to several factors, including developments in genetic sequencing technologies, a rise in understanding concerning risks of inherited diseases, the broader availability of clinical genetic testing services, the development of testing programs in oncology and neurology, and a decrease in the expenses associated with genetic testing.

The predictive and presymptomatic testing market is projected to experience robust expansion in the coming years, anticipated to reach $9.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period can be primarily attributed to the increasing demand for personalized medicine, the rising integration of AI in genomic analysis, the expansion of population-scale screening programs, an enhanced focus on preventive healthcare strategies, and increasing regulatory support for genetic diagnostics. Furthermore, significant trends expected over this period include the growing adoption of preventive genetic screening, a rising utilization of risk-based disease prediction models, the expansion of genetic counseling services, an intensified focus on early disease detection, and the integration of genomic data into clinical decision-making.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20594&type=smp

What Drivers Are Shaping The Development Of The Predictive And Presymptomatic Testing Market?

The growing occurrence of genetic disorders is projected to fuel the expansion of the predictive and presymptomatic testing market moving forward. These disorders are conditions stemming from deoxyribonucleic acid (DNA) irregularities, such as gene mutations and chromosome alterations, exemplified by conditions like cystic fibrosis and Down syndrome. The rising incidence of genetic disorders can be linked to elements like advanced maternal age, various environmental factors, and enhancements in diagnostic methodologies. Predictive and presymptomatic testing is vital for decreasing the prevalence of genetic disorders by identifying at-risk individuals prior to symptom onset. This forward-looking strategy enables early interventions or lifestyle modifications, which can help avert or lessen the seriousness of these conditions. For instance, in June 2023, data from the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, indicated that the volume of gene therapies in Phase III clinical trials increased by 10% in quarter 3, 2023, marking the initial quarterly rise since quarter 3, 2022. Consequently, the increasing prevalence of genetic disorders is acting as a catalyst for the predictive and presymptomatic testing market.

What Segment Types Are Examined In The Predictive And Presymptomatic Testing Market?

The predictive and presymptomatic testing market covered in this report is segmented –

1) By Test Type: Predictive Testing, Presymptomatic Testing

2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications

3) By End User: Hospitals And Clinics, Diagnostic Laboratories

Subsegments:

1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders

2) By Presymptomatic Testing: Huntington’s Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer’s Disease Testing, Presymptomatic Genetic Testing for Familial Diseases

What Long-Term Trends Are Expected To Shape The Future Of The Predictive And Presymptomatic Testing Market?

Within the predictive and presymptomatic testing market, leading companies are concentrated on creating innovative multi-gene testing solutions. These solutions feature advanced genetic risk-scoring to facilitate earlier disease detection and refine personalized prevention approaches. Polygenic panels integrate the sequencing of clinically significant hereditary-risk genes with the analysis of numerous common genetic variations. This offers a more thorough and tailored evaluation of an individual’s future disease probability compared to conventional single-gene tests. An example of this advancement is Myriad Genetics Inc., a U.S.-based molecular diagnostics company, which in November 2025, broadened its MyRisk Hereditary Cancer Test. This expanded test now covers 63 clinically actionable genes relevant to over 11 cancer types. This updated panel incorporates next-generation sequencing along with personalized lifetime and five-year cancer-risk estimates, empowering physicians to make proactive clinical decisions. The product improves risk identification, even for individuals lacking strong family histories, and supports focused surveillance, earlier initiation of screenings, and comprehensive preventive care planning.

Who Are The Primary Competitors In The Global Predictive And Presymptomatic Testing Market?

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/predictive-and-presymptomatic-testing-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Predictive And Presymptomatic Testing Market?

North America was the largest region in the predictive and presymptomatic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Predictive And Presymptomatic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20594&type=smp

Browse Through More Reports Similar to the Global Predictive And Presymptomatic Testing Market 2026, By The Business Research Company

Healthcare Predictive Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/healthcare-predictive-analytics-global-market-report

Predictive Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/predictive-analytics-global-market-report

Predictive Maintenance Market Report 2026

https://www.thebusinessresearchcompany.com/report/predictive-maintenance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795